Skip to content

The development and expression of locomotor sensitization to nicotine in the presence of ibogaine.

C Zubaran, M Shoaib, I P Stolerman

Behavioural Pharmacology August 1, 2000 DOI: 10.1097/00008877-200008000-00009 (opens in new tab)

Read Full Text
Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Preclinical study Peer reviewed
Sample size 10
Population Rats
Interventions Ibogaine Nicotine
Dose 0.0, 5.0 or 10 mg/kg i.p. ibogaine; 0.0 or 0.4 mg/kg s.c. nicotine
Duration 21-day daily co-administration, followed by dose-response testing
Topics Ibogaine
Keywords Psychoactive Addiction treatment Natural compound Nicotine sensitization Nicotine adaptation Enhanced physical reaction Physiological response Nicotine effect Addiction research Substance abuse Drug dependence Pharmacological study Preclinical study Rat model
Citations 7
Key points Co-administration of ibogaine with nicotine over 21 days had no effect on the development or expression of sensitization to nicotine's locomotor stimulant effect in rats.

Abstract

Ibogaine is a naturally occurring psychoactive alkaloid with claimed efficacy in the treatment of certain drug addictions, including nicotine. It has been reported to be a non-competitive blocker of nicotinic receptors, with a potent inhibitory action on nicotinic acetylcholine receptor-mediated catecholamine release. We have investigated the effect of different doses of ibogaine on the development and expression of sensitization to the locomotor stimulant effect of nicotine in rats, a facilitatory process in which a history of exposure to nicotine results in enhanced locomotor activity when the same dose of nicotine is administered repeatedly. The effects were determined of co-administering ibogaine (0.0, 5.0 or 10 mg/kg i.p.) with nicotine (0.0 or 0.4 mg/kg s.c.) daily for 21 days. Dose-response curves for nicotine (0.04-0.8 mg/kg s.c.) were then determined in groups of 10 rats. There was clear sensitization of the locomotor activity produced by nicotine in photocell activity cages but co-administration of ibogaine with nicotine had no effect on the degree of sensitization. Ibogaine (5-20 mg/kg) itself did not influence locomotor activity and was also without effect on the expression of the sensitized response to 0.4 mg/kg of nicotine (n = 10). Thus, there was no evidence that ibogaine may retard or suppress sensitization to nicotine.

Comparable studies

Other preclinical and animal studies on ibogaine, most cited first.

Study Year Design Participants
Noncompetitive Functional Inhibition at Diverse, Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine TE671/RD cells (human muscle-type nAChR) and SH-SY5Y neuroblastoma cells (human... 1999 In vitro study
Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Ibogaine- or harmaline-treated rats 1993 Experimental animal study
Effects and aftereffects of ibogaine on morphine self-administration in rats. Rats 1991 Preclinical experimental study
Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Rats 1994 Experimental study
Glial Cell Line-Derived Neurotrophic Factor Mediates the Desirable Actions of the Anti-Addiction Drug Ibogaine against Alcohol Consumption Rats 2005 Experimental study

Citations in the library

Cited by 1

Cites 16

and 11 more in the library

Related reading

Explore topics

Ibogaine Addiction